U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H20N2O3
Molecular Weight 288.3416
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MORSUXIMIDE

SMILES

CC1(CC(=O)N(CN2CCOCC2)C1=O)C3=CC=CC=C3

InChI

InChIKey=WCHQWOQHNBKKDS-UHFFFAOYSA-N
InChI=1S/C16H20N2O3/c1-16(13-5-3-2-4-6-13)11-14(19)18(15(16)20)12-17-7-9-21-10-8-17/h2-6H,7-12H2,1H3

HIDE SMILES / InChI

Molecular Formula C16H20N2O3
Molecular Weight 288.3416
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Morsuximide is succinimide derivative patented by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt. as an antiepileptic agent. In cats, Morsuximide had mild hypnotic effects when given i.p., and the status epileptic induced by Tetracor was brought under control. Tetracor, given after the administration of Morsuximide, caused only subconvulsive seizures in cats accompanied by an occasional jerk of the skeletal musculature. When 16 epileptic patients were treated with oral Morsuximide (1.0-2.0 g. daily for an av. of 42 days) the drug produced a favorable effect in all forms of human epilepsy, particularly in cases of psychomotor attacks, atypical forms, and petit mal. The major type of epilepsy (grand mal) did not respond to the drug therapy as markedly as the other forms, although drug caused some improvement in these cases.

Originator

Sources: HU151425, " Succinimide derivatives with pharmaceutical effect", Seres, Jeno; Tardos, Laszlo; Leszkovszky, Gyorgy

Approval Year

PubMed

PubMed

TitleDatePubMed
Antiepileptic value of succinimide derivatives. Results of animal experiment and clinical investigations concerning N-methyl-alpha-phenyl succinimide and alpha-methyl-alpha-phenyl-N-morpholinyl-methylene succinimide.
1966
Patents

Sample Use Guides

1.0-2.0 g. daily for an av. of 42 days
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:04:50 GMT 2023
Edited
by admin
on Sat Dec 16 16:04:50 GMT 2023
Record UNII
57G776P4EJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MORSUXIMIDE
INN   WHO-DD  
INN  
Official Name English
2-METHYL-N-(MORPHOLINOMETHYL)-2-PHENYLSUCCINIMIDE
Systematic Name English
S-210
Code English
Morsuximide [WHO-DD]
Common Name English
morsuximide [INN]
Common Name English
S-21O
Code English
Classification Tree Code System Code
NCI_THESAURUS C264
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C66202
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
FDA UNII
57G776P4EJ
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
SMS_ID
100000080391
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
PUBCHEM
71165
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
CAS
3780-72-1
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105127
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
EVMPD
SUB09072MIG
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
INN
3181
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID60863274
Created by admin on Sat Dec 16 16:04:50 GMT 2023 , Edited by admin on Sat Dec 16 16:04:50 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY